



MEN

**FIRST CANCER SITE
KAPOSI SARCOMA**
**KAPOSI SARCOMA
POOL AIRTUM 1976-2010, MEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**SARCOMA DI KAPOSI
POOL AIRTUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	2445		2605		2605		2445		1960		990		355		2445	2605
Person-years ▶	12085		12506		421		1818		5574		3250		1443		12085	12506
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND KAPOSI SARCOMA	238	1.11	257	1.16	19	3.00	50	1.76	104	1.08	59	0.98	25	0.83	2.83	1.88
HEAD AND NECK	7	0.86	7	0.83	0	0.00	1	0.88	4	1.07	0	0.00	2	1.88	-0.11	-0.10
ORAL CAVITY	2	1.01	2	0.98	0	0.00	0	0.00	1	1.11	0	0.00	1	3.80	0.00	0.00
PHARYNX	2	1.17	2	1.13	0	0.00	1	4.23	0	0.00	0	0.00	1	4.44	0.02	0.02
LARYNX	3	0.67	3	0.65	0	0.00	0	0.00	3	1.46	0	0.00	0	0.00	-0.13	-0.12
OESOPHAGUS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.18	-0.18
STOMACH	9	0.69	10	0.74	1	2.49	3	1.68	2	0.34	2	0.56	2	1.18	-0.27	-0.33
COLON RECTUM	34	1.16	37	1.22	3	3.53	7	1.84	11	0.84	11	1.32	5	1.19	0.54	0.38
COLON	16	0.79	17	0.81	1	1.72	3	1.15	5	0.56	5	0.86	3	1.02	-0.31	-0.36
RECTUM	18	1.98	20	2.13	2	7.40	4	3.31	6	1.47	6	2.36	2	1.59	0.85	0.74
LIVER	12	1.37	13	1.44	1	3.84	1	0.86	4	1.01	6	2.45	1	0.82	0.32	0.27
GALLBLADDER	6	2.35	6	2.29	0	0.00	1	2.98	2	1.75	3	4.21	0	0.00	0.27	0.29
PANCREAS	3	0.49	3	0.48	0	0.00	1	1.27	1	0.37	0	0.00	1	1.15	-0.26	-0.25
LUNG	18	0.49	20	0.53	2	1.81	4	0.81	8	0.49	5	0.50	1	0.20	-1.40	-1.52
SKIN MELANOMA	4	1.31	5	1.60	1	11.56	0	0.00	2	1.50	2	2.26	0	0.00	0.15	0.08
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.09
KAPOSI SARCOMA	1	1.62	1	1.56	0	0.00	0	0.00	0	0.00	1	5.93	0	0.00	0.03	0.03
SOFT TISSUE	3	3.81	3	3.70	0	0.00	1	9.55	0	0.00	2	8.99	0	0.00	0.18	0.18
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
PROSTATE	56	1.35	57	1.33	1	0.87	10	1.93	24	1.31	15	1.26	7	1.13	1.14	1.20
TESTIS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
KIDNEY AND RENAL PELVIS	7	1.12	9	1.40	2	11.10	1	1.24	3	1.08	2	1.13	1	1.13	0.21	0.06
BLADDER AND URINARY TRACT	19	0.78	19	0.76	0	0.00	6	1.85	7	0.64	3	0.44	3	0.88	-0.49	-0.45
URINARY BLADDER	19	0.81	19	0.79	0	0.00	6	1.93	7	0.67	3	0.46	3	0.92	-0.40	-0.36
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.09
BRAIN AND CENTRAL NERVOUS SYSTEM	1	0.41	1	0.40	0	0.00	1	3.02	0	0.00	0	0.00	0	0.00	-0.12	-0.12
THYROID	1	1.01	1	0.98	0	0.00	0	0.00	1	2.29	0	0.00	0	0.00	0.00	0.00
HODGKIN LYMPHOMA	2	4.26	2	4.11	0	0.00	2	27.61	0	0.00	0	0.00	0	0.00	0.12	0.13
NON-HODGKIN LYMPHOMA	30	4.93	34	5.43	4	22.05	9	11.12	17	6.24	4	2.34	0	0.00	2.22	1.98
MYELOMA	6	2.03	7	2.30	1	11.53	0	0.00	6	4.55	0	0.00	0	0.00	0.32	0.25
LEUKAEMIAS	7	1.31	7	1.28	0	0.00	0	0.00	5	2.08	1	0.67	1	1.38	0.12	0.14
LYMPHOID LEUKAEMIAS	4	1.59	4	1.54	0	0.00	0	0.00	2	1.75	1	1.43	1	2.93	0.11	0.12
MYELOID LEUKAEMIAS	3	1.26	3	1.23	0	0.00	0	0.00	3	2.82	0	0.00	0	0.00	0.04	0.05
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
OTHER AND ILL DEFINED SITES	13	1.07	16	1.28	3	8.40	2	1.25	7	1.29	3	0.87	1	0.58	0.28	0.07

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE

KAPOSI SARCOMA

KAPOSI SARCOMA
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

SARCOMA DI KAPOSI
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	904	950		950		904		756		377		130		904	950
Person-years ▶	4523	4677		154		683		2166		1186		488		4523	4677	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND KAPOSI SARCOMA	60	1.03	66	1.09	6	3.18	10	1.18	28	1.01	14	0.90	8	1.22	0.35	1.22
HEAD AND NECK	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.15	-0.15
ORAL CAVITY	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.09
PHARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OESOPHAGUS	1	3.14	1	3.04	0	0.00	0	0.00	1	6.54	0	0.00	0	0.00	0.15	0.14
STOMACH	2	0.49	2	0.48	0	0.00	0	0.00	2	1.02	0	0.00	0	0.00	-0.45	-0.47
COLON RECTUM	11	1.13	11	1.09	0	0.00	4	2.85	4	0.86	1	0.38	2	1.81	0.27	0.20
COLON	9	1.27	9	1.23	0	0.00	2	1.97	4	1.19	1	0.53	2	2.48	0.42	0.36
RECTUM	2	0.75	2	0.72	0	0.00	2	5.10	0	0.00	0	0.00	0	0.00	-0.15	-0.16
LIVER	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.42	-0.42
GALLBLADDER	2	1.27	2	1.23	0	0.00	0	0.00	1	1.33	1	2.41	0	0.00	0.09	0.08
PANCREAS	2	0.72	2	0.70	0	0.00	0	0.00	0	0.00	2	2.66	0	0.00	-0.17	-0.18
LUNG	2	0.57	3	0.82	1	8.96	0	0.00	2	1.20	0	0.00	0	0.00	-0.34	-0.14
SKIN MELANOMA	3	3.34	4		1	35.23	1	7.89	0	0.00	1	4.12	1	9.64	0.47	0.66
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
KAPOSI SARCOMA	1	8.34	1	8.05	0	0.00	0	0.00	0	0.00	1	32.77	0	0.00	0.19	0.19
SOFT TISSUE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	13	1.04	15	1.16	2	4.93	1	0.55	6	1.01	4	1.21	2	1.42	0.12	0.45
CERVIX UTERI	1	1.54	1	1.49	0	0.00	0	0.00	1	3.17	0	0.00	0	0.00	0.08	0.07
CORPUS UTERI	1	0.45	1	0.44	0	0.00	0	0.00	0	0.00	0	0.00	1	4.12	-0.27	-0.27
OVARY	1	0.59	1	0.57	0	0.00	0	0.00	1	1.24	0	0.00	0	0.00	-0.15	-0.16
KIDNEY AND RENAL PELVIS	2	1.55	2	1.50	0	0.00	0	0.00	1	1.64	0	0.00	1	6.72	0.16	0.14
BLADDER AND URINARY TRACT	3	1.23	3	1.19	0	0.00	1	2.87	1	0.87	1	1.53	0	0.00	0.13	0.10
URINARY BLADDER	3	1.33	3	1.29	0	0.00	1	3.09	1	0.93	1	1.65	0	0.00	0.16	0.14
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
BRAIN AND CENTRAL NERVOUS SYSTEM	1	1.25	1	1.21	0	0.00	0	0.00	0	0.00	0	0.00	1	11.17	0.04	0.04
THYROID	1	1.39	1	1.35	0	0.00	0	0.00	0	0.00	1	5.11	0	0.00	0.06	0.06
HODGKIN LYMPHOMA	1	8.34	2	16.09	1	228.36	0	0.00	0	0.00	1	33.15	0	0.00	0.19	0.40
NON-HODGKIN LYMPHOMA	6	2.89	6	2.80	0	0.00	1	3.30	4	4.03	1	1.82	0	0.00	0.87	0.82
MYELOMA	1	0.93	1	0.90	0	0.00	0	0.00	1	1.95	0	0.00	0	0.00	-0.02	-0.02
LEUKAEMIAS	1	0.61	2	1.18	1	18.59	0	0.00	0	0.00	1	2.30	0	0.00	-0.14	0.06
LYMPHOID LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.16	-0.16
MYELOID LEUKAEMIAS	1	1.33	1	1.29	0	0.00	0	0.00	0	0.00	1	5.00	0	0.00	0.06	0.05
OTHER LEUKAEMIAS	0	0.00	1	5.65	1	185.05	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	0.18
OTHER AND ILL DEFINED SITES	5	0.94	5	0.91	0	0.00	2	2.64	3	1.19	0	0.00	0	0.00	-0.07	-0.10

Decrease/Difetto
Increase/Eccesso

Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio